JULIE CONRAD: Open Payments
NPI 1639698822 · CLERMONT, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,911 in 214 payments from 17 companies in 2025. Trend: 2023 $2,932 · 2024 $3,088 · 2025 $3,911
Food & beverage: $3,911
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 37 | $796 |
| Teva Pharmaceuticals USA, Inc. | 38 | $443 |
| Otsuka America Pharmaceutical, Inc. | 15 | $431 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $322 |
| Alkermes, Inc. | 12 | $311 |
| Janssen Pharmaceuticals, Inc | 14 | $298 |
| Vanda Pharmaceuticals Inc. | 12 | $294 |
| ABBVIE INC. | 30 | $268 |
| Axsome Therapeutics, Inc. | 8 | $218 |
| E.R. Squibb & Sons, L.L.C. | 12 | $211 |
Products named: INGREZZA, REXULTI, CAPLYTA, INVEGA SUSTENNA, VRAYLAR, UZEDY, Auvelity, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
